Diabetes drug with heart attack link 'should never have been issued'

'British Medical Journal' says Avandia should be withdrawn from the UK market. Jeremy Laurance reports

One of the world's biggest-selling drugs for diabetes should never have been licensed and should now be withdrawn, says the British Medical Journal. It says its investigation into concerns about the drug, Avandia, made by British multinational GlaxoSmithKline, which has been linked with increased heart attacks, are too great to allow its continued use.

The BMJ claims that the UK drug regulator, the Medicines and Healthcare Products Regulatory Authority, was advised by the Commission on Human Medicines to withdraw the drug last July, but it remains on the market because the European Medicines Agency, which licenses drugs across Europe, has yet to reach a decision on Avandia, whose chemical name is rosiglitazone. The advice from the Commission said the "risks of rosiglitazone outweigh its benefits and it no longer has a place on the UK market".

Fiona Godlee, editor-in-chief of the BMJ, said the drug "should not have been licensed and should now be withdrawn". She called for "more robust regulatory processes and better access to the raw data used to license drugs to allow scrutiny by the scientific community".

Avandia is also the subject of a BBC Panorama programme, to be broadcast tonight, which is expected to raise similar concerns about the drug regulatory process. GSK disputes the BMJ's allegations. It has previously maintained that its trials were conducted responsibly and that the drug is safe when adminstered correctly.

When Avandia was lauched in the UK in 2000, the drug was hailed as a turning-point in the treatment of diabetes . It was one of the first of a new class of drugs for the condition – called glitazones – to be developed since the 1950s. Sales soared until 2007 when a review in the New England Journal of Medicine showed a significant increase in the risk of heart attack associated with the drug.

The BMJ investigation, based on documents obtained under the Freedom of Information Act, concluded there was a "paucity of evidence" during the European approval process a decade ago, and some experts involved in the process were concerned about long-term risks and benefits.

The report also raises concerns about the quality of the data used by GSK to show that rosiglitazone did not lead to increased heart problems compared to other diabetes drugs, the lack of publicly available trial results for independent scientific scrutiny, a lack of transparency in the European system, and the ability of the European regulator to assess individual patient data.

Since July, the MHRA has advised doctors in the UK to consider alternative treatments where appropriate. Those at a higher risk of heart disease should be advised to stop taking the drug. The same month, a panel of 33 medical experts, convened by the US Food and Drugs Administration, concluded, after a two-day hearing, that Avandia was safe enough to stay on the market. Last March, after research by the Mayo Clinic in Minnesota, which does not rely on commercial sponsorship, the BMJ said nine out of 10 scientists who backed Avandia had financial links to the pharmaceutical industry. Fewer than 30 per cent of those with financial links with the industry expressed "unfavourable views" of Avandia. The research did not suggest any attempt by GSK to influence the debate.

The BMJ today says: "The scandal of rosiglitazone lies in the fact that we were prescribing the drug to reduce the serious consequences of Type 2 diabetes, the most important of which is myocardial infarction [heart attack]. Yet because no licensing body demanded evidence of effect on cardiovascular risk at the time of licensing, 10 years after the release of rosiglitazone we still cannot accurately quantify the harm to which we were exposing our patients."

GSK said: "GSK has carried out an extensive research programme involving more than 50,000 patients to analyse the safety and benefits of rosiglitazone. No other diabetes medicine introduced in the past 10 years has such an extensive safety database. We reject any suggestion that there is a lack of publicly available trial results related to rosiglitazone for independent scientific scrutiny."

PROMOTED VIDEO
Life and Style
ebooksA superb mix of recipes serving up the freshest of local produce in a delicious range of styles
Life and Style
ebooksFrom the lifespan of a slug to the distance to the Sun: answers to 500 questions from readers
Life and Style
tech

Company reveals $542m investment in start-up building 'a rocket ship for the mind"

News
Bourgogne wine maker Laboure-Roi vice president Thibault Garin (L) offers the company's 2013 Beaujolais Nouveau wine to the guest in the wine spa at the Hakone Yunessun spa resort facilities in Hakone town, Kanagawa prefecture, some 100-kilometre west of Tokyo
i100
Arts and Entertainment
James Blunt's debut album Back to Bedlam shot him to fame in 2004
music

Singer says the track was 'force-fed down people's throats'

Sport
CSKA Moscow celebrate after equalising with a late penalty
football

News
i100
Latest stories from i100
Have you tried new the Independent Digital Edition apps?

ES Rentals

    Independent Dating
    and  

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    IT Project Manager

    Competitive: Clearwater People Solutions Ltd: Our client based in Chelmsford a...

    Business Intelligence Specialist - work from home

    £40000 per annum: Ashdown Group: An established and growing IT Consultancy fir...

    Business Intelligence Specialist - work from home

    £40000 per annum: Ashdown Group: An established and growing IT Consultancy fir...

    IT Manager

    £40000 - £45000 per annum + pension, healthcare,25 days: Ashdown Group: An est...

    Day In a Page

    Two super-sized ships have cruised into British waters, but how big can these behemoths get?

    Super-sized ships: How big can they get?

    Two of the largest vessels in the world cruised into UK waters last week
    British doctors on brink of 'cure' for paralysis with spinal cord treatment

    British doctors on brink of cure for paralysis

    Sufferers can now be offered the possibility of cure thanks to a revolutionary implant of regenerative cells
    Let's talk about loss

    We need to talk about loss

    Secrecy and silence surround stillbirth
    Will there be an all-female mission to Mars?

    Will there be an all-female mission to Mars?

    Women may be better suited to space travel than men are
    Oscar Pistorius sentencing: The athlete's wealth and notoriety have provoked a long overdue debate on South African prisons

    'They poured water on, then electrified me...'

    If Oscar Pistorius is sent to jail, his experience will not be that of other inmates
    James Wharton: The former Guard now fighting discrimination against gay soldiers

    The former Guard now fighting discrimination against gay soldiers

    Life after the Army has brought new battles for the LGBT activist James Wharton
    Ebola in the US: Panic over the virus threatens to infect President Obama's midterms

    Panic over Ebola threatens to infect the midterms

    Just one person has died, yet November's elections may be affected by what Republicans call 'Obama's Katrina', says Rupert Cornwell
    Premier League coaches join the RSC to swap the tricks of their trades

    Darling, you were fabulous! But offside...

    Premier League coaches are joining the RSC to learn acting skills, and in turn they will teach its actors to play football. Nick Clark finds out why
    How to dress with authority: Kirsty Wark and Camila Batmanghelidjh discuss the changing role of fashion in women's workwear

    How to dress with authority

    Kirsty Wark and Camila Batmanghelidjh discuss the changing role of fashion in women's workwear
    New book on Joy Division's Ian Curtis sheds new light on the life of the late singer

    New book on Ian Curtis sheds fresh light on the life of the late singer

    'Joy Division were making art... Ian was for real' says author Jon Savage
    Sean Harris: A rare interview with British acting's secret weapon

    Sean Harris: A rare interview with British acting's secret weapon

    The Bafta-winner talks Hollywood, being branded a psycho, and how Barbra Streisand is his true inspiration
    Tim Minchin, interview: The musician, comedian and world's favourite ginger is on scorching form

    Tim Minchin interview

    For a no-holds-barred comedian who is scathing about woolly thinking and oppressive religiosity, he is surprisingly gentle in person
    Boris Johnson's boozing won't win the puritan vote

    Boris's boozing won't win the puritan vote

    Many of us Brits still disapprove of conspicuous consumption – it's the way we were raised, says DJ Taylor
    Ash frontman Tim Wheeler reveals how he came to terms with his father's dementia

    Tim Wheeler: Alzheimer's, memories and my dad

    Wheeler's dad suffered from Alzheimer's for three years. When he died, there was only one way the Ash frontman knew how to respond: with a heartfelt solo album